NEW YORK (GenomeWeb News) – Genomic service firms ImaGenes and Fasteris said today that they have entered into a partnership to provide next-generation sequencing services in Germany and Austria.
Under the terms of the agreement, ImaGenes of Berlin, Germany, will act as a local distributor for Fasteris’ sequencing services in Germany and Austria. ImaGenes, founded in 2007 as a spin-off from the German Resource Center for Genome Research, specializes in microarray-based genomic services.
Fasteris, based in Geneva, Switzerland, offers a range of sequencing services based on the Illumina Genome Analyzer platform, including small RNA, ChIP-Seq, and transcriptome analysis; gene expression profiling; de novo sequencing; and whole-genome or targeted re-sequencing for the detection of genetic variants.
Fasteris said that it has developed bar-coding protocols for preparing genomic, small RNA, or gene expression samples and has installed a paired-end module for the Illumina system that “facilitates de novo sequence assembly and identification of variants such as insertions or deletions.”
Steffen Hennig, director of bioinformatics and services at ImaGenes, said in a statement that the addition of Fasteris' sequencing technology to its offerings will provide the firm with new genomic or transcriptome sequence information that it can use to design new microarrays.
He added that the company also plans to offer SAGE and CAGE analyses on the Fasteris sequencer, “adding a new dimension to studies of transcript regulation.”